The objectives and performance contract

Published on 20 November 2024

The Agence de la biomédecine’s 2022-2026 objectives and performance contract signed with the French State is a strategic document that formally and contractually documents the agency’s main strategic directions in terms of contributing to public health priorities, in coordination with all its institutional partners (supervisory bodies, agency system, national health insurance fund, regional health agencies, health institutions, etc.).

A strengthened strategic framework

Signed on 14 February 2023, the 2022-2026 objectives and performance contract marks a strategic shift for the Agence de la biomédecine against a backdrop of major legislative changes and growing societal expectations. It focuses on the agency’s objectives as part of its duties as a public administrative institution.

Complementarity with ministerial plans

The 2022-2026 objectives and performance contract complements the three ministerial plans that set the national priorities for the agency’s areas of expertise, identifying the specific activities to be carried out over the next five years with a view to measuring performance and efficiency in light of the resources allocated to the agency’s work.

Two main strategic focuses

The contract has two principal focuses:

“medical and scientific” aspects: this section sets three strategic objectives aimed at strengthening the agency’s medical and scientific activities.
“cross-functional” aspects: this section sets seven strategic objectives that act as levers in improving the agency’s performance and efficiency in carrying out its duties.

By including these objectives, the objectives and performance contract ensures that the agency is effectively supervised, thereby ensuring that the resources allocated are optimally used.